Malignant gliomas, with an incidence of 5 cases per 100,000 population per year, represent the most common primary brain tumour. They have an overall survival length of less than 2 years. Many different adjuvant therapies have been developed. Among them, Photodynamic Therapy (PDT), that is based on photochemical reactions between light and tumoral tissue selectively labelled with exogenous photosensitizing agents. Among photosensitizers, m-THPC (Temoporfin), seems to be the most promising one for the treatment of brain tumors, but, unfortunately, it causes problems of high skin photosensitivity. To by-pass this problem, we devised an intratumoral route of administration of this photosensitizer. The aim of this study is to investigate and compare the uptake of m-THPC in brain tumor and normal tissue after systemic and intratumoral administration of the drug. 30 female Wistar rats received m-THPC 12 days after C6 tumor implantation. Temoporfin was administered intratumorally in 24 rats at two different concentrations. 6 rats constituted the control group and received m-THPC by means of an intraperitoneal injection. The brains were extracted at 4 h, 24 hand 96 h after Temoporfin injection. The samples were examined with a confocal laser scanning microscope. All samples showed high fluorescence emission exclusively in the tumour area, without appreciable differences between the samples taken at the different times of sacrifice and the two routes of administration. No fluorescence whatsoever was detected among normal brain tissue surrounding the tumour. The intratumoral route appears to give comparable results to the systemic one, regarding intracellular uptake efficiency and tumour -normal tissue ratio, with the advantage of a much shorter time needed to reach optimal intratumoural concentration -that is just four hours from m-THPC injection.
PDT was initiated by Diamond et al (1972) (3) and Signorelli et al (1978) (4) , and for more than two decades, porpyrins and hematoporphyrin derivatives have been used almost exclusively as photosensitizers in clinical practice. Due to their low uptake rate by tumor cells, below expectations specificityfor tumor tissue and inadequate photoactivation wavelength -conditioning low penetration depth in human brain -the efficacy of PDT was somewhat lower than estimated (5) (6) (7) (8) (9) (10) . Now, a second generation of sensitizers is emerging with improved photophysical and phototoxic profiles for PDT. Of these, metatetrahydroxyphenylchlorin (m-THPC, Temoporfin) is promising for the treatment of brain tumors because of its higher selectivity for tumor cells, of the absorption in the near-infrared region, which supports a deep penetration -that is 1.5-1.8 emof the stimulating light into tumour tissue, and of its greater quantum efficiency, that means more ROS per light dose administered (10) (11) .
Unfortunately, m-THPC causes the same problems ofhigh skinphotosensitivity,thatpersists aftertreatment, as its predecessors, requiring many days during which the patient must be put under light restriction (11) (12) . This renders PDT a more impractical and expensive treatment than it should be. To by-pass this problem, we propose the intratumoral route of administration of this photosensitizer.
Intratumoral delivery of a photosensitizer for brain tumor was tried in the 80s and late 90s in animal and human models using Hematoporphyrin derivative (HeD), (13) (14) (15) . Due to the lack, at the time, of a non-neurotoxic photosensitizer agent, highly selective for brain tumor, results were definitely poor and, thus, intratumoral route was ruled out for PDT and abandoned (15) . Now, a second generation photosensitizer m-THPC seems to have the necessary selectivity for malignant glioma, without any sign of brain toxicity.
On this basis, we carried out this study, with the aim of investigating and comparing the uptake of m-THPC in brain tumor and normal tissue after systemic and intratumoral administration ofthe drug.
MATERIALS AND METHODS
Tumor model C6 glioma cells were grown at 37°C with 5% carbon dioxide and 97% humidity in DMEM medium supplemented with 10% fetal calf serum, not-essential aminoacids, 100 U/ml penicillin and 100 ug/ml streptomycin.
30 female Wistar rats (Breeding and Experimental Centre of Catholic University, Rome, Italy), weighing approximately 300 g, were anaesthetized with a mixture of Ketamine (74 mg /Kg), Xylazine (1.7 mg/Kg), Acepromazine (1.4 mg/Kg), injected in the peritoneum. After anaesthesia, on each rat a scalp incision was performed along the midline and the right coronal suture was exposed; using a n? 11 scalpel, we made a burr hole located at the coronal suture 3 mm right of the midline. The rats were then put on a stereotactic frame specifically designed for rats and, after trypsinization, 1 x 10 6 glioma cells (volume 10 Ill) were stereotacticly injected with a Hamilton syringe through the burr hole at a depth of 4 mm into the right frontal lobe. The hole was then closed with bone wax and the scalp sutured with a 2-0 ethilon wire.
The same anesthesia and the same surgical technique was applied for all intracranial procedures.
Photosensitizer administration
Temoporfin was administered in a pharmaceutical solution of 40% ethanol and 60% ethylene glycol (Foscan®; Biolitec AG, lena, Germany). The mixture contained 4 mg/ml m-THPC.
Twelve days after tumour injection, the animals were divided into three groups and received the photosensitizer according to the following modalities:
Group A (6 rats) peritoneal injection of 0.3 mg/Kg (0.09 mg) Foscan® (volume 0.5 ml);
Group B (12 rats) intratumoral injection of 0.02 mg/ Kg (0.006 mg) Foscan® (volume 10 Ill; 1 Ill/min), at the same coordinates of C6 cell implant;
Group C (12 rats) intratumoral injection of 0,015 mg/ Kg (0,0045 mg) Foscan® (volume 10 Ill; 1 Ill/min), at the same coordinates of C6 cell implant.
The intratumoral doses we adopted arise from a compromise between the systemic dose and the time interval for maximum uptake; in particular, it was one of the main concerns of our study to find out the ideal dose in order to obtain maximum uptake of photosensitizer in the shortest time possible from drug administration. Pursuing these aims, data indicated by Kostron et al (0.3 mg/Kg systemic dose of radiolabelled m-THPC, with a concentration of 0.16 mg/ml and a disintegration rate of 71909 d.p.m./ml, results in a tumoral disintegration rate -that is, uptakeof 223664 d.p.m./g and in a normal brain disintegration rate of 5336 d.p.m./g) have been taken as a reference in a preliminary phase of this study (unpublished data). During this phase, we proceeded to test intraneoplastic doses 50 (corresponding to calculated tumoral uptake after systemic administration), 40 and A B Fig. 1. A. Micrograph showing the tumor, its periphery and normal brain area. The arrow indicates the tumor core (H&E). B: ofthe same area. Maximumfluorescence (arrow) corresponds to the tumor core. Fluorescence extends to the periphery and it is absent from normal brain tissue.
Fig. 2. Confocal scan micrograph showing "vescicular" intracytoplasmaticfluorescence (arrows), due to m-THPC localization inside endoplasmic reticulum and Golgi bodies.
30 times lower than the systemic one, observing an inhomogeneous photosensitization with a late maximum uptake, after more than 12 hours from drug administration. Intratumoral doses described in this paper (20 and 15 times lower than systemic one) are those that allowed a homogeneous maximum m-THPC uptake after only 4 hours from drug delivery. An intraneoplastic dose 10 times lower than the systemic one has been ruled out, because it was associated to epileptic seizures in some animals.
During the whole experiment, the rats were maintained in a 12 hours light/l2 hours dark regimen and they were observed for the occurrence of neurological deficits or adverse effects of m-THPC, especially skin toxicity.
The rats were killed according to the following scheme:
Group A: 24 hours after Foscan® administration; Groups Band C: 4 h, 24 hand 96 h after Foscan® injection, in groups of four.
Preparation ofsamples
After killing the rats, the brains were removed intact and sectioned at the point of tumour implant, then they were frozen in liquid nitrogen and stored at -80°C.
The tumors were clearly visible at the naked eye. 5 urn thick coronal sections of the brains were examined with a confocal laser scanning microscope (Leica TCS, Leica Microsystems, Mannheim -Germany), equipped with an Ar/Kr laser. After excitation at 558 nrn wavelength, fluorescence emission was collected using a 488/543 nm filter and a 550-700 nm spectral window.
RESULTS
Samples taken from animals treated with systemic Temoporfin administration showed high fluorescence emission exclusively in the tumour area ( Fig. 1 a, b) .
All samples coming from rats treated with intratumoral photosensitizer administration showed similar results, without appreciable differences between the samples taken at the different times of sacrifice. No fluorescence whatsoever was detected among normal brain tissue surrounding the tumour (Fig. 1 a, b) . High magnification images showed intracytoplasmatic localization of m-THPC (Fig. 2) .
No signs whatsoever of either neurological deficits or skin toxicity were observed.
DISCUSSION
Born at the beginning of the 70s, PDT was subsequently put aside due to lower than expected results, joined with a relatively high frequency of adverse effects (5) .
In the last few years, the creation of the so-called second generation photosensitizers, like m-THPC, made PDT, once again, a promising adjuvant therapy for brain tumours (10) (11) 16) .
Temoporfin, as a matter of fact, has a higher sensitivity and specificity for neoplastic tissue due to its active uptake through LDL receptor, with a tumour/normal tissue ratio of almost 100:1 (17) (18) .
Furthermore, the high excitation wavelength (652 nm) and the relative potency of Temoporfin allow a deep penetration of light into the surrounding brain, resulting in a deep biological effect with the aim of destroying the infiltrating malignant cells (11, 19) .
However, the problem of skin sensibilization persists, causing patient distress, and a prolonged and expensive stay at the hospital with dedicated facilities to avoid accidentalillumination of the patient.
In order to by-pass the problems related to systemic administration, we devised this experimental study with the aim of verifying the feasibility and the advantages of an intratumoral administration of m-THPC.
The results exceeded expectations. Observations with confocal microscope showed comparable intratumoral distribution of Temoporfin between intratumoral and systemic administration of the drug, even with a 20 times lower intratumoral dose and after just 4 hours from the m-THPC injection. Furthermore, normal tissue presented no fluorescence emission in any specimen we analyzed.
Highly magnified images showed intense cytoplasmic fluorescent activity, with "vescicular" morphology. These data agree with recent literature that identifies endoplamic reticulum and Golgi bodies as m-THPC's main localization sites (18) . According to our results, the intratumoral route appears to give results comparable to the systemic one, regarding uptake efficiency and tumour -normal tissue ratio, with the advantage of a much shorter time needed to reach optimal intratumoural concentration -that is just four hours from m-THPC injection.
Our data suggest that topical route of m-THPC administration could represent a safe and efficient strategy to remarkably reduce hospitalization time and costs for patients that are eligible for PDT.
